We are Orphinic Scientific

We develop first-in-class or best-in-class projects which have potential to become life-changing therapies

Orphinic Scientific focuses on high quality assets in orphan
diseases
in line with proven business model of similar development companies.

We focus on therapeutics but also look at diagnostics, medical devices, and e-Health.

Please contact Orphinic for more information about the pipeline

Ambulero is a Miami, US-based biotechnology company dedicated to advancing a platform of cell and gene therapies to treat serious vascular diseases. Ambulero holds an exclusive license from the University of Miami to develop and commercialize research that was shown to promote vascular repair and regeneration. Orphinic Scientific participates in a global development of Ambulero’s breakthrough gene therapy that has a potential to reduce risk of limb ulcers and amputation in patients affected by vascular diseases. For more information,

Vasa Therapeutics is a biotechnology company focused on development of novel therapies for heart failure and other serious cardiovascular diseases. With offices in San Diego, California, and Wrocław, Poland, Vasa Therapeutics comprises an international team of scientists with a proven track record of successful drug development. In 2020, Vasa Therapeutics was awarded a 2.6 million Euro grant from the EU regional development fund to discover and develop an innovative drug candidate program for heart failure with preserved ejection fraction (HFpEF). Funding from Orphinic Scientific will support further growth of the company, including expansion of its therapeutic pipeline.